Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
11.11
+0.44 (4.12%)
At close: Mar 9, 2026, 4:00 PM EDT
11.11
0.00 (0.00%)
Pre-market: Mar 10, 2026, 4:58 AM EDT
Phathom Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Phathom Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $19.5, which forecasts a 75.52% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $28.
Price Target: $19.5 (+75.52%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Phathom Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $20 → $25 | Strong Buy | Maintains | $20 → $25 | +125.02% | Feb 27, 2026 |
| Barclays | Barclays | Hold Initiates $16 | Hold | Initiates | $16 | +44.01% | Dec 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $26 | Strong Buy | Maintains | $20 → $26 | +134.02% | Oct 31, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $17 | Strong Buy | Maintains | $12 → $17 | +53.02% | Jun 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +80.02% | Jun 9, 2025 |
Financial Forecast
Revenue This Year
335.55M
from 175.11M
Increased by 91.62%
Revenue Next Year
536.26M
from 335.55M
Increased by 59.82%
EPS This Year
-0.82
from -3.03
EPS Next Year
1.10
from -0.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 351.8M | 599.8M | |||
| Avg | 335.6M | 536.3M | |||
| Low | 303.7M | 479.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 100.9% | 78.7% | |||
| Avg | 91.6% | 59.8% | |||
| Low | 73.4% | 42.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 1.83 | |||
| Avg | -0.82 | 1.10 | |||
| Low | -1.16 | 0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.